(Q40800372)

23 September 2017

title

Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients (English)

1 reference

23 September 2017

main subject

anti-retroviral agent

0 references

17

Max Essex

1 reference

23 September 2017

16

Mark A Wainberg

1 reference

23 September 2017

7

Ndwapi Ndwapi

1 reference

23 September 2017

Florence Doualla-Bell

1

object named as

Florence Doualla-Bell

1 reference

23 September 2017

15

Ibou Thior

1 reference

23 September 2017

13

Richard Marlink

1 reference

23 September 2017

12

Peter Cardiello

1 reference

23 September 2017

2

Simane Gaseitsiwe

1 reference

23 September 2017

6

Vladimir Novitsky

1 reference

23 September 2017

3

Thumbi Ndungú

1 reference

23 September 2017

author name string

Musetsanagepe Modukanele

4

1 reference

23 September 2017

Trevor Peter

5

1 reference

23 September 2017

Gaolathe Tendani

8

1 reference

23 September 2017

Ava Avalos

9

1 reference

23 September 2017

William Wester

10

1 reference

23 September 2017

Hermann Bussmann

11

1 reference

23 September 2017

Howard Moffat

14

1 reference

23 September 2017

publication date

1 July 2004

1 reference

Antiviral Chemistry & Chemotherapy

23 September 2017

published in

1 reference

23 September 2017

volume

15

1 reference

23 September 2017

issue

4

1 reference

23 September 2017

page(s)

189-200

1 reference

A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500402

Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500402

Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500402

Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500402

Clinical uses of non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500402

A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500402

Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500402

Drug resistance in non-subtype B HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500402

Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500402

Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500402

Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500402

Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500402

Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500402

Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500402

A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500402

Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500402

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500402

The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500402

10.1177/095632020401500402

21 January 2018

Identifiers

DOI

1 reference

23 September 2017

1 reference